Adaptimmune Inc. (NASDAQ: ADAP) stock gained by 20.85% in the pre-market trading session. Adaptimmune is a clinical-stage pharmaceutical firm focusing on developing new cancer immunotherapy medicines for cancer patients. The SPEAR T-cell platform, developed by the company, allows T-cells to be engineered to target and eradicate cancer in a variety of solid tumors.
>> 7 Top Picks for the Post-Pandemic Economy <<
ADAP stock’ Current Development
Adaptimmune Therapeutics has established a strategic partnership and license agreement with Genentech which is a Roche Group company, to develop and market allogeneic cell treatments for a variety of cancer conditions.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
There are two parts to the collaboration:
- Allogeneic T-cell treatments for up to five common cancer targets are being developed.
- Personalized allogeneic T-cell treatments are being developed.
Adaptimmune will be in charge of developing clinical candidates for each component using its allogeneic platform developed from induced pluripotent stem cells to manufacture T-cells. Genentech will be in charge of the input TCRs, as well as clinical research and commercialization.
Moreover,
Adaptimmune will receive a $150 million upfront payment and subsequent installments of $150 million over the next five years unless the arrangement is terminated early. In addition, Adaptimmune could be eligible for payments totaling more than $3 billion in research, development, regulatory, and commercial milestones.
On Thursday, September 9, ADAP will give a live virtual update to explain its allogeneic platform and future development goals.
>> 7 Top Picks for the Post-Pandemic Economy <<
Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer stated,
Given Genentech’s dedication to patients and science in the field of cancer immunology, they are honored to collaborate with them. Adaptimmune’s leadership position in developing allogeneic cell treatments is strengthened by this partnership, which builds on their extensive experience obtained from their autologous clinical trials. Their platform will be the foundation of a personalized allogeneic cell therapy vision in which every patient can receive a T-cell product for their cancer as a result of their collaboration, which is a huge step toward their aim of making cell treatments both curative and mainstream.